CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); C12N 5/16 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2510/00 (2013.01)] | 21 Claims |
1. A population of immune cells, which comprises genetically engineered T cells, wherein the genetically engineered T cells comprise:
(i) a disrupted Regnase-1 (Reg1) gene;
(ii) a disrupted Transforming Growth Factor Beta Receptor II (TGFBRII) gene; and
(iii) a nucleic acid encoding a chimeric antigen receptor (CAR) that binds a tumor antigen.
|